<SEC-DOCUMENT>0001615774-16-007394.txt : 20160927
<SEC-HEADER>0001615774-16-007394.hdr.sgml : 20160927
<ACCEPTANCE-DATETIME>20160927074642
ACCESSION NUMBER:		0001615774-16-007394
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160921
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160927
DATE AS OF CHANGE:		20160927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		161903349

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s104220_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
September 21, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NEKTAR THERAPEUTICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact Name of Registrant as Specified
in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 2pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; padding-right: 2pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-24006</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 2pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3134940</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State or Other Jurisdiction</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of Incorporation)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File Number)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS Employer</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>455 Mission Bay Boulevard South</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>San Francisco, California 95128</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices
and Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (415) 482-5300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item&nbsp;1.01</B></TD><TD><B>Entry into a Material Definitive Agreement.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 21, 2016, Nektar Therapeutics,
a Delaware corporation (&ldquo;Nektar&rdquo;), entered into a Clinical Trial Collaboration Agreement (the &ldquo;Agreement&rdquo;)
with Bristol-Myers Squibb Company, a Delaware corporation (&ldquo;BMS&rdquo;), pursuant to which Nektar and BMS will collaborate
to conduct Phase 1/2 clinical trials evaluating Nektar&rsquo;s IL-2-based CD122-biased agonist, known as NKTR-214, and BMS&rsquo;s
human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types
and seven potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon
by the parties (each, a &ldquo;Combined Therapy Trial&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Agreement, BMS will be responsible
for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories,
clinical sites and institutional review boards. Each party will otherwise be responsible for its own internal costs, including
internal personnel costs, incurred in connection with each Combined Therapy Trial. Nektar and BMS will use commercially reasonable
efforts to manufacture and supply its compound for each Combined Therapy Trial and will bear the costs related thereto. The parties
will form a joint development committee to oversee clinical trial design, regulatory strategy, and other activities necessary to
conduct and support the Combined Therapy Trials. Nektar will act as sponsor of each Combined Therapy Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ownership of, and global commercial rights
to, NKTR-214 remain solely with Nektar under the Agreement. If Nektar wishes to license the right to commercialize NKTR-214 in
one of certain major market territories prior to September 30, 2018 (the &ldquo;Exclusivity Expiration Date&rdquo;), Nektar must
first negotiate with BMS, for a period of three months (the &ldquo;Negotiation Period&rdquo;), to grant an exclusive license to
develop and commercialize NKTR-214 in any of these major market territories. If BMS and Nektar do not reach an agreement for an
exclusive license within the Negotiation Period, Nektar will be free to license any right to NKTR-214 to other parties in any territory
worldwide except that in the event that Nektar receives a license offer from a third party during a period of 90 calendar days
after the end of the Negotiation Period, Nektar will provide BMS ten business days to match the terms of such third-party offer.
After the Exclusivity Expiration Date, Nektar is free to license NKTR-214 without any further obligation to BMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each party grants to the other party a non-exclusive,
worldwide (subject to certain exceptions in the case of the license granted by BMS), non-transferable and royalty-free research
and development license to such licensing party&rsquo;s patent rights, technology and regulatory documentation to use its compound
solely to the extent necessary to discharge its obligations under the Agreement with respect to the conduct of the Combined Therapy
Trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Agreement also contains certain reciprocal
exclusivity provisions that run until the Exclusivity Expiration Date. Nektar agrees not to conduct any preclinical or clinical
research with, or grant rights under its proprietary intellectual property or relevant investigational new drug applications to,
certain restricted third parties regarding an anti-PD-1 antagonist or anti-PD-L1 antagonist together with the NKTR-214 (a &ldquo;Restricted
NKTR-214 Combination&rdquo;), and BMS agrees not to conduct any preclinical or clinical research with certain restricted third
parties regarding Nivolumab together with an IL2-based CD122 agonist (a &ldquo;Restricted Nivolumab Combination&rdquo;). Nektar
and BMS remain free to conduct any preclinical or clinical research&mdash;involving a Restricted NKTR-214 Combination in the case
of Nektar and a Restricted Nivolumab Combination in the case of BMS&mdash;on their own or in collaboration with academic or other
non-profit entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to termination rights for breach,
bankruptcy or a material safety issue/clinical hold, the term of the Agreement will continue in effect until completion by all
centers or institutions participating in the Combined Therapy Trials, the delivery of study data to both parties and the completion
of any then agreed upon protocol, statistical analysis and bioanalysis plan. In the event a third party merges with or acquires
Nektar, Nektar is free to assign or transfer the Agreement without the consent of BMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing summary does not purport to
be complete and is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to Nektar&rsquo;s
Quarterly Report on Form 10-Q for the period ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item&nbsp;7.01</B></TD><TD><B>Regulation FD Disclosure.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 27, 2016, BMS and Nektar jointly
issued a press release attached hereto as Exhibit 99.1 (&ldquo;Press Release&rdquo;), announcing the entry into the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this Item 7.01, including
Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liability of that section, nor shall such information
be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933,
as amended, or the Exchange Act, except as otherwise stated in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item&nbsp;8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 27, 2016, Nektar announced
that it would hold a Webcast conference call on September 27, 2016, at 9:00 a.m. Eastern Time to review the collaboration with
BMS and give an update on the NKTR-214 development program. This conference call is accessible through a link that is posted on
the home page and Investor Relations section of the Nektar website: <U>http://www.nektar.com</U>. On this conference call, management
expects to make certain forward-looking statements regarding the therapeutic potential of NKTR-214 both as a single agent and in
combination with other cancer therapies such as Nivolumab, the potential benefits of the BMS collaboration, plans and expectations
for the conduct and completion of future clinical studies, and certain other forward looking statements regarding Nektar&rsquo;s
business. These forward-looking statements involve substantial risks and uncertainties including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NKTR-214
is in early-stage clinical development and there are substantial risks that can unexpectedly occur for numerous reasons, including
negative safety and efficacy findings in the ongoing Phase 1/2 clinical study notwithstanding positive findings from interim clinical
results and preclinical studies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical observations from the ongoing Phase 1/2 clinical trial of NKTR-214 are based on preliminary data from an ongoing clinical
trial that is still actively enrolling patients and these preliminary data may not be representative of final results after all
patients complete the trial and all data are collected and analyzed. Further, this preliminary data is subject to continuing audit
and verification procedures that will not be complete until the conclusion of the trial and therefore the interim data is subject
to change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to
regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory
requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory
approval in one or more important markets; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
discovery of new medical breakthroughs is an inherently uncertain process and the future success of applying our technology platform
to potential new drug candidates (such as NKTR-214) is therefore highly uncertain and unpredictable and one or more research and
development programs could fail;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
may not issue from our patent applications for our drug candidates including NKTR-214, patents that have issued may not be enforceable,
or additional intellectual property licenses from third parties may be required; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
important risks and uncertainties set forth in Nektar&rsquo;s Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on August 4, 2016 and available at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Actual results could differ materially from
the forward-looking statements made by management during the conference call and in the Press Release. Nektar undertakes no obligation
to update forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: left"><B>Item&nbsp;9.01</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release titled &ldquo;Bristol-Myers Squibb and Nektar Therapeutics Form Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214&rdquo; issued on September 27, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nektar Therapeutics</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 27, 2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gil M. Labrucherie</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil M. Labrucherie</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Senior Vice President and Chief Financial Officer</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 1pt; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release titled &ldquo;Bristol-Myers Squibb and Nektar Therapeutics Form Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214&rdquo; issued on September 27, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s104220_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Bristol-Myers Squibb and Nektar Therapeutics
Announce Oncology Clinical Collaboration to Evaluate the Combination of <I>Opdivo</I> (nivolumab) and NKTR-214 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>New collaboration will explore the potential
benefits of combining Bristol-Myers Squibb&rsquo;s anti-PD-1 antibody with Nektar&rsquo;s CD122-biased agonist in five tumor types</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<B>SAN FRANCISCO and NEW YORK, September 27, 2016)</B> - Bristol-Myers
Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq: NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers
Squibb&rsquo;s <I>Opdivo</I> (nivolumab) with Nektar&rsquo;s investigational medicine, NKTR-214, as a potential combination treatment
regimen in five tumor types and seven potential indications. <I>Opdivo </I>is a PD-1 immune checkpoint inhibitor designed to overcome
immune suppression. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells
and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&ldquo;We are
excited to explore the potential benefits in multiple types of cancer of the combination of <I>Opdivo</I> with Nektar&rsquo;s innovative
cancer immunotherapy,&rdquo; said Fouad Namouni, M.D., Head of Oncology Development, Bristol-Myers Squibb. &ldquo;We believe that
a combination regimen which utilizes two different and complementary mechanisms designed to harness the body&rsquo;s own immune
system to fight cancer has the potential to provide new treatment options for patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Phase 1/2 clinical trials will evaluate
the potential for the combination of <I>Opdivo</I> and NKTR-214 to show improved and sustained efficacy and tolerability above
the current standard of care in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients. An initial dose-escalation
trial is underway with <I>Opdivo</I> and NKTR-214.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bristol-Myers Squibb and Nektar will equally
share costs of the combined therapy trials. Nektar will maintain its global commercial rights to NKTR-214.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&ldquo;We&rsquo;re
very pleased to be collaborating with Bristol-Myers Squibb, a global leader in immuno-oncology, in order to advance quickly the
development of NKTR-214 with a PD-1 immune checkpoint inhibitor,&rdquo; said Howard W. Robin, President and CEO of Nektar Therapeutics.
&ldquo;NKTR-214 is designed to grow tumor infiltrating lymphocytes (TILs)&nbsp;<I>in vivo</I> and replenish the immune system,
which is critically important as many patients battling cancer lack sufficient TIL populations to benefit from approved checkpoint
inhibitor therapies.&nbsp; T<FONT STYLE="background-color: #FEFEFE">he combination of checkpoint inhibition with T cell growth
</FONT>could lead to synergistic effects that may provide a new treatment option for patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Opdivo</I> was the first PD-1 immune
checkpoint inhibitor to receive regulatory approval anywhere in the world in&nbsp;July 2014, and currently has regulatory approval
in 54 countries including&nbsp;the United States,&nbsp;Japan, and in the&nbsp;European Union.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NKTR-214 is an experimental therapy designed
to stimulate cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune
cells, known as CD8+ effector T cells and Natural Killer (NK) cells. In preclinical studies, treatment with NKTR-214 resulted in
a rapid expansion of these cells and mobilization into the tumor micro-environment.<SUP>1,2</SUP> NKTR-214 has an antibody-like
dosing regimen similar to the existing checkpoint inhibitor class of approved medicines. A Phase 1/2 clinical study is ongoing
to evaluate single-agent NKTR-214 in cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Bristol-Myers Squibb &amp; Immuno-Oncology: Advancing
Oncology Research</U></B><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At Bristol-Myers Squibb, we have a vision for the future of
cancer care that is focused on Immuno-Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy
and targeted therapies for certain types of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a comprehensive clinical portfolio of investigational
and approved Immuno-Oncology agents, many of which were discovered and developed by our scientists. Our ongoing Immuno-Oncology
clinical program is looking at broad patient populations, across multiple solid tumors and hematologic malignancies, and lines
of therapy and histologies, with the intent of powering our trials for overall survival and other important measures like durability
of response. We pioneered the research leading to the first regulatory approval for the combination of two Immuno-Oncology agents
and continue to study the role of combinations in cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also investigating other immune system pathways in the
treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO and LAG-3. These pathways may lead to potential
new treatment options &ndash; in combination or monotherapy &ndash; to help patients fight different types of cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our collaboration with academia, as well as small and large
biotech and pharmaceutical companies, to research the potential of Immuno-Oncology and non-Immuno-Oncology combinations helps achieve
our goal of providing new treatment options in clinical practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At Bristol-Myers Squibb, we are committed to changing survival
expectations in hard-to-treat cancers and the way patients live with cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About <I>Opdivo</I> </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cancer cells may exploit &ldquo;regulatory&rdquo; pathways,
such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. <I>Opdivo</I> is a PD-1 immune
checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells, and blocks the binding of PD-L1
and PD-L2, preventing the PD-1 pathway&rsquo;s suppressive signaling on the immune system, including the interference with an anti-tumor
immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Opdivo&rsquo;s</I> broad global development program is based
on Bristol-Myers Squibb&rsquo;s understanding of the biology behind Immuno-Oncology. Our company is at the forefront of researching
the potential of Immuno-Oncology to extend survival in hard-to-treat cancers. This scientific expertise serves as the basis for
the <I>Opdivo</I> development program, which includes a broad range of Phase 3 clinical trials evaluating overall survival as the
primary endpoint across a variety of tumor types. The <I>Opdivo </I>trials have also contributed toward the clinical and scientific
understanding of the role of biomarkers and how patients may benefit from <I>Opdivo</I> across the continuum of PD-L1 expression.
To date, the <I>Opdivo</I> clinical development program has enrolled more than 18,000 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>U.S.<FONT STYLE="font-size: 10pt"> </FONT>INDICATIONS
&amp; IMPORTANT SAFETY INFORMATION </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>INDICATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPDIVO&reg; (nivolumab) as a single agent is indicated for the
treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPDIVO&reg; (nivolumab) as a single agent is indicated for the
treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated
approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description
of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPDIVO&reg; (nivolumab), in combination with YERVOY&reg; (ipilimumab),
is indicated for the treatment of patients with unresectable or metastatic melanoma. This indication is approved under accelerated
approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description
of clinical benefit in the confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPDIVO<SUP>&reg;</SUP>&nbsp;(nivolumab) is indicated for the
treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations
prior to receiving OPDIVO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPDIVO<SUP>&reg;</SUP>&nbsp;(nivolumab) is indicated for the
treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OPDIVO&reg; (nivolumab) is indicated for
the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic
stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin. This indication is approved under accelerated approval
based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical
benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please refer to the end of the Important Safety Information
for a brief description of the patient populations studied in the CheckMate trials.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>IMPORTANT SAFETY INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>YERVOY can result in severe and fatal immune-mediated adverse
reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse
reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The
majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months
after discontinuation of YERVOY. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Assess patients for signs and symptoms of enterocolitis,
dermatitis, neuropathy, and endocrinopathy and evaluate clinical chemistries including liver function tests (LFTs), adrenocorticotropic
hormone (ACTH) level, and thyroid function tests at baseline and before each dose.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Permanently discontinue YERVOY and initiate systemic high-dose
corticosteroid therapy for severe immune-mediated reactions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Pneumonitis </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immune-mediated pneumonitis, including
fatal cases, occurred with OPDIVO treatment. Across the clinical trial experience with solid tumors, fatal immune-mediated pneumonitis
occurred with OPDIVO. In addition, in Checkmate 069, there were six patients who died without resolution of abnormal respiratory
findings. Monitor patients for signs with radiographic imaging and symptoms of pneumonitis. Administer corticosteroids for Grade
2 or greater pneumonitis. Permanently discontinue for Grade 3 or 4 and withhold until resolution for Grade 2. In Checkmate 069
and 067, immune-mediated pneumonitis occurred in 6% (25/407) of patients receiving OPDIVO with YERVOY: Fatal (n=1), Grade 3 (n=6),
Grade 2 (n=17), and Grade 1 (n=1). In Checkmate 037, 066, and 067, immune-mediated pneumonitis occurred in 1.8% (14/787) of patients
receiving OPDIVO: Grade 3 (n=2) and Grade 2 (n=12). In Checkmate 057, immune-mediated pneumonitis, including interstitial lung
disease, occurred in 3.4% (10/287) of patients: Grade 3 (n=5), Grade 2 (n=2), and Grade 1 (n=3). In Checkmate 025, pneumonitis,
including interstitial lung disease, occurred in 5% (21/406) of patients receiving OPDIVO and 18% (73/397) of patients receiving
everolimus. Immune-mediated pneumonitis occurred in 4.4% (18/406) of patients receiving OPDIVO: Grade 4 (n=1), Grade 3 (n=4), Grade
2 (n=12), and Grade 1 (n=1). In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 4.9% (13/263)
of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 3.4% (9/263) of patients receiving OPDIVO: Grade 3 (n=1)
and Grade 2 (n=8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Colitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immune-mediated colitis can occur with OPDIVO treatment. Monitor
patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 (of more than 5 days duration), 3, or 4 colitis.
As a single agent, withhold OPDIVO for Grade 2 or 3 and permanently discontinue for Grade 4 or recurrent colitis upon restarting
OPDIVO. When administered with YERVOY, withhold OPDIVO for Grade 2 and permanently discontinue for Grade 3 or 4 or recurrent colitis
upon restarting OPDIVO. In Checkmate 069 and 067, diarrhea or colitis occurred in 56% (228/407) of patients receiving OPDIVO with
YERVOY. Immune-mediated colitis occurred in 26% (107/407) of patients: Grade 4 (n=2), Grade 3 (n=60), Grade 2 (n=32), and Grade
1 (n=13). In Checkmate 037, 066, and 067, diarrhea or colitis occurred in 31% (242/787) of patients receiving OPDIVO. Immune-mediated
colitis occurred in 4.1% (32/787) of patients: Grade 3 (n=20), Grade 2 (n=10), and Grade 1 (n=2). In Checkmate 057, diarrhea or
colitis occurred in 17% (50/287) of patients receiving OPDIVO. Immune-mediated colitis occurred in 2.4% (7/287) of patients: Grade
3 (n=3), Grade 2 (n=2), and Grade 1 (n=2). In Checkmate 025, diarrhea or colitis occurred in 25% (100/406) of patients receiving
OPDIVO and 32% (126/397) of patients receiving everolimus. Immune-mediated diarrhea or colitis occurred in 3.2% (13/406) of patients
receiving OPDIVO: Grade 3 (n=5), Grade 2 (n=7), and Grade 1 (n=1). In Checkmate 205 and 039, diarrhea or colitis occurred in 30%
(80/263) of patients receiving OPDIVO. Immune-mediated diarrhea (Grade 3) occurred in 1.1% (3/263) of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening,
or fatal (diarrhea of &ge;7 stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred
in 34 (7%) patients. Across all YERVOY-treated patients in that study (n=511), 5 (1%) developed intestinal perforation, 4 (0.8%)
died as a result of complications, and 26 (5%) were hospitalized for severe enterocolitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Hepatitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immune-mediated hepatitis can occur with OPDIVO treatment. Monitor
patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater
transaminase elevations. Withhold for Grade 2 and permanently discontinue for Grade 3 or 4 immune-mediated hepatitis. In Checkmate
069 and 067, immune-mediated hepatitis occurred in 13% (51/407) of patients receiving OPDIVO with YERVOY: Grade 4 (n=8), Grade
3 (n=37), Grade 2 (n=5), and Grade 1 (n=1). In Checkmate 037, 066, and 067, immune-mediated hepatitis occurred in 2.3% (18/787)
of patients receiving OPDIVO: Grade 4 (n=3), Grade 3 (n=11), and Grade 2 (n=4). In Checkmate 057, one patient (0.3%) developed
immune-mediated hepatitis. In Checkmate 025, there was an increased incidence of liver test abnormalities compared to baseline
in AST (33% vs 39%), alkaline phosphatase (32% vs 32%), ALT (22% vs 31%), and total bilirubin (9% vs 3.5%) in the OPDIVO and everolimus
arms, respectively. Immune-mediated hepatitis requiring systemic immunosuppression occurred in 1.5% (6/406) of patients receiving
OPDIVO: Grade 3 (n=5) and Grade 2 (n=1). In Checkmate 205 and 039, hepatitis occurred in 11% (30/263) of patients receiving OPDIVO.
Immune-mediated hepatitis occurred in 3.4% (9/263): Grade 3 (n=7) and Grade 2 (n=2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening,
or fatal hepatotoxicity (AST or ALT elevations &gt;5x the ULN or total bilirubin elevations &gt;3x the ULN; Grade 3-5) occurred
in 8 (2%) patients<I>,</I> with fatal hepatic failure in 0.2% and hospitalization in 0.4%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Dermatitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening,
or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness
dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) patients. 1 (0.2%) patient
died as a result of toxic epidermal necrolysis. 1 additional patient required hospitalization for severe dermatitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Neuropathies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, 1 case of fatal
Guillain-Barr&eacute; syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Endocrinopathies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hypophysitis, adrenal insufficiency, thyroid disorders, and
type 1 diabetes mellitus can occur with OPDIVO treatment. Monitor patients for signs and symptoms of hypophysitis, signs and symptoms
of adrenal insufficiency during and after treatment, thyroid function prior to and periodically during treatment, and hyperglycemia.
Administer corticosteroids for Grade 2 or greater hypophysitis. Withhold for Grade 2 or 3 and permanently discontinue for Grade
4 hypophysitis. Administer corticosteroids for Grade 3 or 4 adrenal insufficiency. Withhold for Grade 2 and permanently discontinue
for Grade 3 or 4 adrenal insufficiency. Administer hormone-replacement therapy for hypothyroidism. Initiate medical management
for control of hyperthyroidism. Administer insulin for type 1 diabetes. Withhold OPDIVO for Grade 3 and permanently discontinue
for Grade 4 hyperglycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In Checkmate 069 and 067, hypophysitis occurred in 9% (36/407)
of patients receiving OPDIVO with YERVOY: Grade 3 (n=8), Grade 2 (n=25), and Grade 1 (n=3). In Checkmate 037, 066, and 067, hypophysitis
occurred in 0.9% (7/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=3), and Grade 1 (n=2). In Checkmate 025, hypophysitis
occurred in 0.5% (2/406) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 1 (n=1). In Checkmate 069 and 067, adrenal insufficiency
occurred in 5% (21/407) of patients receiving OPDIVO with YERVOY: Grade 4 (n=1), Grade 3 (n=7), Grade 2 (n=11), and Grade 1 (n=2).
In Checkmate 037, 066, and 067, adrenal insufficiency occurred in 1% (8/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade
2 (n=5), and Grade 1 (n=1). In Checkmate 057, 0.3% (1/287) of OPDIVO-treated patients developed adrenal insufficiency. In Checkmate
025, adrenal insufficiency occurred in 2.0% (8/406) of patients receiving OPDIVO: Grade 3 (n=3), Grade 2 (n=4), and Grade 1 (n=1).
In Checkmate 205 and 039, adrenal insufficiency (Grade 2) occurred in 0.4% (1/263) of patients receiving OPDIVO. In Checkmate 069
and 067, hypothyroidism or thyroiditis occurred in 22% (89/407) of patients receiving OPDIVO with YERVOY: Grade 3 (n=6), Grade
2 (n=47), and Grade 1 (n=36). Hyperthyroidism occurred in 8% (34/407) of patients: Grade 3 (n=4), Grade 2 (n=17), and Grade 1 (n=13).
In Checkmate 037, 066, and 067, hypothyroidism or thyroiditis occurred in 9% (73/787) of patients receiving OPDIVO: Grade 3 (n=1),
Grade 2 (n=37), Grade 1 (n=35). Hyperthyroidism occurred in 4.4% (35/787) of patients receiving OPDIVO: Grade 3 (n=1), Grade 2
(n=12), and Grade 1 (n=22). In Checkmate 057, Grade 1 or 2 hypothyroidism, including thyroiditis, occurred in 7% (20/287) and elevated
thyroid stimulating hormone occurred in 17% of patients receiving OPDIVO. Grade 1 or 2 hyperthyroidism occurred in 1.4% (4/287)
of patients. In Checkmate 025, thyroid disease occurred in 11% (43/406) of patients receiving OPDIVO, including one Grade 3 event,
and in 3.0% (12/397) of patients receiving everolimus. Hypothyroidism/thyroiditis occurred in 8% (33/406) of patients receiving
OPDIVO: Grade 3 (n=2), Grade 2 (n=17), and Grade 1 (n=14). Hyperthyroidism occurred in 2.5% (10/406) of patients receiving OPDIVO:
Grade 2 (n=5) and Grade 1 (n=5). In Checkmate 205 and 039, hypothyroidism/thyroiditis occurred in 12% (32/263) of patients receiving
OPDIVO: Grade 2 (n=18) and Grade 1: (n=14). Hyperthyroidism occurred in 1.5% (4/263) of patients receiving OPDIVO: Grade 2: (n=3)
and Grade 1 (n=1). In Checkmate 069 and 067, diabetes mellitus or diabetic ketoacidosis occurred in 1.5% (6/407) of patients: Grade
4 (n=3), Grade 3 (n=1), Grade 2 (n=1), and Grade 1 (n=1). In Checkmate 037, 066, and 067, diabetes mellitus or diabetic ketoacidosis
occurred in 0.8% (6/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=3), and Grade 1 (n=1). In Checkmate 025, hyperglycemic
adverse events occurred in 9% (37/406) patients. Diabetes mellitus or diabetic ketoacidosis occurred in 1.5% (6/406) of patients
receiving OPDIVO: Grade 3 (n=3), Grade 2 (n=2), and Grade 1 (n=1). In Checkmate 205 and 039, diabetes mellitus occurred in 0.8%
(2/263) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 1 (n=1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, severe to life-threatening
immune-mediated endocrinopathies (requiring hospitalization, urgent medical intervention, or interfering with activities of daily
living; Grade 3-4) occurred in 9 (1.8%) patients. All 9&nbsp;patients had hypopituitarism, and some had additional concomitant
endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism. 6 of the 9 patients were hospitalized for severe
endocrinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Nephritis and Renal Dysfunction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immune-mediated nephritis can occur with
OPDIVO treatment. Monitor patients for elevated serum creatinine prior to and periodically during treatment. For Grade 2 or 3 increased
serum creatinine, withhold and administer corticosteroids; if worsening or no improvement occurs, permanently discontinue. Administer
corticosteroids for Grade 4 serum creatinine elevation and permanently discontinue. In Checkmate 069 and 067, immune-mediated nephritis
and renal dysfunction occurred in 2.2% (9/407) of patients: Grade 4 (n=4), Grade 3 (n=3), and Grade 2 (n=2). In Checkmate 037,
066, and 067, nephritis and renal dysfunction of any grade occurred in 5% (40/787) of patients receiving OPDIVO. Immune-mediated
nephritis and renal dysfunction occurred in 0.8% (6/787) of patients: Grade 3 (n=4) and Grade 2 (n=2). In Checkmate 057, Grade
2 immune-mediated renal dysfunction occurred in 0.3% (1/287) of patients receiving OPDIVO. In Checkmate 025, renal injury occurred
in 7% (27/406) of patients receiving OPDIVO and 3.0% (12/397) of patients receiving everolimus. Immune-mediated nephritis and renal
dysfunction occurred in 3.2% (13/406) of patients receiving OPDIVO: Grade 5 (n=1), Grade 4 (n=1), Grade 3 (n=5), and Grade 2 (n=6).
In Checkmate 205 and 039, nephritis and renal dysfunction occurred in 4.9% (13/263) of patients treated with OPDIVO. This included
one reported case (0.3%) of Grade 3 autoimmune nephritis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Immune-Mediated Rash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immune-mediated rash can occur with OPDIVO
treatment. Severe rash (including rare cases of fatal toxic epidermal necrolysis) occurred in the clinical program of OPDIVO. Monitor
patients for rash. Administer corticosteroids for Grade 3 or 4 rash. Withhold for Grade 3 and permanently discontinue for Grade
4. In Checkmate 069 and 067, immune-mediated rash occurred in 22.6% (92/407) of patients receiving OPDIVO with YERVOY: Grade 3
(n=15), Grade 2 (n=31), and Grade 1 (n=46). In Checkmate 037, 066, and 067, immune-mediated rash occurred in 9% (72/787) of patients
receiving OPDIVO: Grade 3 (n=7), Grade 2 (n=15), and Grade 1 (n=50). In Checkmate 057, immune-mediated rash occurred in 6% (17/287)
of patients receiving OPDIVO including four Grade 3 cases. In Checkmate 025, rash occurred in 28% (112/406) of patients receiving
OPDIVO and 36% (143/397) of patients receiving everolimus. Immune-mediated rash, defined as a rash treated with systemic or topical
corticosteroids, occurred in 7% (30/406) of patients receiving OPDIVO: Grade 3 (n=4), Grade 2 (n=7), and Grade 1 (n=19). In Checkmate
205 and 039, rash occurred in 22% (58/263) of patients receiving OPDIVO. Immune-mediated rash occurred in 7% (18/263) of patients
on OPDIVO: Grade 3 (n=4), Grade 2 (n=3), and Grade 1 (n=11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Immune-Mediated Encephalitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immune-mediated encephalitis can occur with OPDIVO treatment.
Withhold OPDIVO in patients with new-onset moderate to severe neurologic signs or symptoms and evaluate to rule out other causes.
If other etiologies are ruled out, administer corticosteroids and permanently discontinue OPDIVO for immune-mediated encephalitis.
In Checkmate 067, encephalitis was identified in one patient (0.2%) receiving OPDIVO with YERVOY. In Checkmate 057, fatal limbic
encephalitis occurred in one patient (0.3%) receiving OPDIVO. In Checkmate 205 and 039, encephalitis occurred in 0.8% (2/263) of
patients after allogeneic HSCT after OPDIVO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Immune-Mediated Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the severity of adverse reaction, permanently discontinue
or withhold treatment, administer high-dose corticosteroids, and, if appropriate, initiate hormone-replacement therapy. In &lt;
1.0% of patients receiving OPDIVO, the following clinically significant, immune-mediated adverse reactions occurred: uveitis, iritis,
pancreatitis, facial and abducens nerve paresis, demyelination, polymyalgia rheumatica, autoimmune neuropathy, Guillain-Barr&eacute;
syndrome, hypopituitarism, systemic inflammatory response syndrome, gastritis, duodenitis, and sarcoidosis. Across clinical trials
of OPDIVO as a single agent administered at doses of 3 mg/kg and 10&nbsp;mg/kg, additional clinically significant, immune-mediated
adverse reactions were identified: motor dysfunction, vasculitis, and myasthenic syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Infusion Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Severe infusion reactions have been reported
in &lt;1.0% of patients in clinical trials of OPDIVO. Discontinue OPDIVO in patients with Grade 3 or 4 infusion reactions. Interrupt
or slow the rate of infusion in patients with Grade 1 or 2. In Checkmate 069 and 067, infusion- related reactions occurred in 2.5%
(10/407) of patients receiving OPDIVO with YERVOY: Grade 2 (n=6) and Grade 1 (n=4). In Checkmate 037, 066, and 067, Grade 2 infusion
related reactions occurred in 2.7% (21/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=8), and Grade 1 (n=11). In
Checkmate 057, Grade 2 infusion reactions requiring corticosteroids occurred in 1.0% (3/287) of patients receiving OPDIVO. In Checkmate
025, hypersensitivity/infusion-related reactions occurred in 6% (25/406) of patients receiving OPDIVO and 1.0% (4/397) of patients
receiving everolimus. In Checkmate 205 and 039, hypersensitivity/infusion-related reactions occurred in 16% (42/263) of patients
receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=24), and Grade 1 (n=16).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Complications of Allogeneic HSCT after
OPDIVO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Complications, including fatal events,
occurred in patients who received allogeneic HSCT after OPDIVO. Outcomes were evaluated in 17 patients from Checkmate 205 and 039,
who underwent allogeneic HSCT after discontinuing OPDIVO (15 with reduced-intensity conditioning, 2 with myeloablative conditioning).
Thirty-five percent (6/17) of patients died from complications of allogeneic HSCT after OPDIVO. Five deaths occurred in the setting
of severe or refractory GVHD. Grade 3 or higher acute GVHD was reported in 29% (5/17) of patients. Hyperacute GVHD was reported
in 20% (n=2) of patients. A steroid-requiring febrile syndrome, without an identified infectious cause, was reported in 35% (n=6)
of patients. Two cases of encephalitis were reported: Grade 3 (n=1) lymphocytic encephalitis without an identified infectious cause,
and Grade 3 (n=1) suspected viral encephalitis. Hepatic veno-occlusive disease (VOD) occurred in one patient, who received reduced-intensity
conditioned allogeneic SCT and died of GVHD and multi-organ failure. Other cases of hepatic VOD after reduced-intensity conditioned
allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptor blocking antibody before transplantation.
Cases of fatal hyperacute GVHD have also been reported. These complications may occur despite intervening therapy between PD-1
blockade and allogeneic HSCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Follow patients closely for early evidence
of transplant-related complications such as hyperacute GVHD, severe (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome,
hepatic VOD, and other immune-mediated adverse reactions, and intervene promptly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Embryo-fetal Toxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on their mechanisms of action, OPDIVO and YERVOY can cause
fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive
potential to use effective contraception during treatment with an OPDIVO- or YERVOY- containing regimen and for at least 5 months
after the last dose of OPDIVO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lactation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is not known whether OPDIVO or YERVOY is present in human
milk. Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions
in nursing infants from an OPDIVO-containing regimen, advise women to discontinue breastfeeding during treatment. Advise women
to discontinue nursing during treatment with YERVOY and for 3 months following the final dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Serious Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
Checkmate 067, serious adverse reactions (73% and 37%), adverse reactions leading to permanent discontinuation (43% and 14%) or
to dosing delays (55% and 28%), and Grade 3 or 4 adverse reactions (72% and 44%) all occurred more frequently in the OPDIVO plus
YERVOY arm relative to the OPDIVO arm. The most frequent (&ge;10%) serious adverse reactions in the OPDIVO plus YERVOY arm and
the OPDIVO arm, respectively, were diarrhea (13% and 2.6%), colitis (10% and 1.6%), and pyrexia (10% and 0.6%). In Checkmate 037,
serious adverse reactions occurred in 41% of patients receiving OPDIVO. Grade 3 and 4 adverse reactions occurred in 42% of patients
receiving OPDIVO. The most frequent Grade 3 and 4 adverse drug reactions reported in 2% to &lt;5% of patients receiving OPDIVO
were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066, serious adverse
reactions occurred in 36% of patients receiving OPDIVO. Grade 3 and 4 adverse reactions occurred in 41% of patients receiving OPDIVO.
The most frequent Grade 3 and 4 adverse reactions reported in &ge;2% of patients receiving OPDIVO were gamma-glutamyltransferase
increase (3.9%) and diarrhea (3.4%). In Checkmate 057, serious adverse reactions occurred in 47% of patients receiving OPDIVO.
The most frequent serious adverse reactions reported in &ge;2% of patients were pneumonia, pulmonary embolism, dyspnea, pleural
effusion, and respiratory failure. In Checkmate 025, serious adverse reactions occurred in 47% of patients receiving OPDIVO. The
most frequent serious adverse reactions reported in &ge;2% of patients were acute kidney injury, pleural effusion, pneumonia, diarrhea,
and hypercalcemia. In Checkmate 205 and 039, among all patients (safety population [n=263]), adverse reactions leading to discontinuation
(4.2%) or to dosing delays (23%) occurred. The most frequent serious adverse reactions reported in </FONT><FONT STYLE="font-family: Symbol">&sup3;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">1%
of patients were infusion-related reaction, pneumonia, pleural effusion, pyrexia, rash and pneumonitis. Ten patients died from
causes other than disease progression, including 6 who died from complications of allogeneic HSCT. Serious adverse reactions occurred
in 21% of patients in the safety population (n=263) and 27% of patients in the subset of patients evaluated for efficacy (efficacy
population [n=95]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Checkmate 067, the most common (&ge;20%)
adverse reactions in the OPDIVO plus YERVOY arm were fatigue (59%), rash (53%), diarrhea (52%), nausea (40%), pyrexia (37%), vomiting
(28%), and dyspnea (20%). The most common (&ge;20%) adverse reactions in the OPDIVO arm were fatigue (53%), rash (40%), diarrhea
(31%), and nausea (28%). In Checkmate 037, the most common adverse reaction (&ge;20%) reported with OPDIVO was rash (21%). In Checkmate
066, the most common adverse reactions (&ge;20%) reported with OPDIVO vs dacarbazine were fatigue (49% vs 39%), musculoskeletal
pain (32% vs 25%), rash (28% vs 12%), and pruritus (23% vs 12%). In Checkmate 057, the most common adverse reactions (&ge;20%)
reported with OPDIVO were fatigue (49%), musculoskeletal pain (36%), cough (30%), decreased appetite (29%), and constipation (23%).
In Checkmate 025, the most common adverse reactions (&ge;20%) reported in patients receiving OPDIVO vs everolimus were asthenic
conditions (56% vs 57%), cough (34% vs 38%), nausea (28% vs 29%), rash (28% vs 36%), dyspnea (27% vs 31%), diarrhea (25% vs 32%),
constipation (23% vs 18%), decreased appetite (23% vs 30%), back pain (21% vs 16%), and arthralgia (20% vs 14%). <B> </B>In Checkmate
205 and 039, among all patients (safety population [n=263]) and the subset of patients in the efficacy population (n=95), respectively,
the most common adverse reactions (reported in at least 20%) were fatigue (32% and 43%), upper respiratory tract infection (28%
and 48%), pyrexia (24% and 35%), diarrhea (23% and 30%), and cough (22% and 35%). In the subset of patients in the efficacy population
(n=95), the most common adverse reactions also included rash (31%), musculoskeletal pain (27%), pruritus (25%), nausea (23%), arthralgia
(21%), and peripheral neuropathy (21%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a separate Phase 3 study of YERVOY 3 mg/kg, the most common
adverse reactions (&ge;5%) in patients who received YERVOY at 3&nbsp;mg/kg were fatigue (41%), diarrhea (32%), pruritus (31%),
rash (29%), and colitis (8%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>CHECKMATE Trials and Patient Populations</U></B><BR>
<B>Checkmate 069 and 067 </B>- advanced melanoma alone or in combination with YERVOY; <B>Checkmate 037 and 066</B> - advanced melanoma;
<B>Checkmate 057</B> &ndash; non-squamous non-small cell lung cancer (NSCLC); <B>Checkmate 025</B> - renal cell carcinoma; <B>Checkmate
205/039</B> - classical Hodgkin lymphoma</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Please see U.S. Full Prescribing Information, including Boxed
WARNING regarding immune-mediated adverse reactions, for YERVOY. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Please see U.S. Full Prescribing Information for OPDIVO.
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About the Bristol-Myers Squibb and Ono Pharmaceutical
Co., Ltd. Collaboration</U></B><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2011, through a collaboration agreement with Ono Pharmaceutical
Co., Ltd (Ono), Bristol-Myers Squibb expanded its territorial rights to develop and commercialize <I>Opdivo</I> globally except
in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Bristol-Myers
Squibb and Ono further expanded the companies&rsquo; strategic collaboration agreement to jointly develop and commercialize multiple
immunotherapies &ndash; as single agents and combination regimens &ndash; for patients with cancer in Japan, South Korea and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bristol-Myers Squibb </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information
about Bristol-Myers Squibb, visit us at&nbsp;<U>BMS.com</U>&nbsp;or follow us on <U>LinkedIn</U>,&nbsp;<U>Twitter</U>, <U>YouTube</U>
and <U>Facebook</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bristol-Myers Squibb Forward-Looking Statement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains &quot;forward-looking statements&quot;
as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization
of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially
from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that Opdivo
in combination with a NKTR-214, an immuno-stimulatory therapy designed to grow specific cytotoxic T cells and natural killer (NK)
cells in the body, will receive regulatory approval for the treatment of cancer. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified
in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2015
in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;Nektar Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nektar Therapeutics&nbsp;is a biopharmaceutical company with
a robust, wholly-owned R&amp;D pipeline of investigational medicines in oncology, immunology and pain as well as a portfolio of
approved partnered medicines. Nektar&nbsp;is headquartered in&nbsp;San Francisco,&nbsp;California, with additional operations in&nbsp;Huntsville,
Alabama&nbsp;and&nbsp;Hyderabad,&nbsp;India. Further information about the company and its drug development programs and capabilities
may be found online at&nbsp;<U>http://www.nektar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Opdivo</I> is a registered trademark of Bristol-Myers Squibb.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cautionary Note Regarding Forward-Looking Statements</I></B><I><BR>
This press release contains forward-looking statements which can be identified by words such as: &quot;anticipate,&quot; &quot;intend,&quot;
&quot;plan,&quot; &quot;expect,&quot; &quot;believe,&quot; &quot;should,&quot; &quot;may,&quot; &quot;will&quot; and similar references
to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential
of NKTR-214, the therapeutic potential of NKTR-214 in combination with OPDIVO, and the potential of our technology and drug candidates
in our research and development pipeline.&nbsp; Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business,
future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking
statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual
results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding
the therapeutic potential of NKTR-214 are based on preclinical findings and early observations from the ongoing Phase 1 clinical
study for NKTR-214, (ii) NKTR-214 is in early-stage clinical development and there are substantial risks that can unexpectedly
occur for numerous reasons including negative safety and efficacy findings in the ongoing Phase 1 clinical study notwithstanding
positive findings in preclinical studies; (iii) our drug candidates and those of our collaboration partners are in various stages
of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for
numerous reasons including negative safety and efficacy findings even after positive findings in previous preclinical and clinical
studies; (iv) the timing of the commencement or end of clinical trials and the availability of clinical may be delayed or unsuccessful
due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving
regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining
regulatory approval in one or more important markets; (v) scientific discovery of new medical breakthroughs is an inherently uncertain
process and the future success of applying our technology platform to potential new drug candidates (such as NKTR-214) is therefore
highly uncertain and unpredictable and one or more research and development programs could fail; (vi) patents may not issue from
our patent applications for our drug candidates including NKTR-214, patents that have issued may not be enforceable, or additional
intellectual property licenses from third parties may be required ; and (vii) certain other important risks and uncertainties set
forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission&nbsp;on&nbsp;August 4, 2016. Any forward-looking
statement made by us in this press release is based only on information currently available to us and speaks only as of the date
on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%; font-size: 10pt"><IMG SRC="tlogo1.jpg" ALT=""></td>
    <td style="width: 50%; font-size: 10pt; text-align: right"><IMG SRC="tlogo2.jpg" ALT=""></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact (for Bristol-Myers Squibb):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lisa McCormick Lavery, 609-252-7602, <U>lisa.mccormicklavery@bms.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ken Dominski, 609-252-5251, <U>ken.dominski@bms.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tim Power, 609-252-7509, <U>timothy.power@bms.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bill Szablewski, 609-252-5894, <U>william.szablewski@bms.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts (for Nektar):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jennifer Ruddock&nbsp;of&nbsp;Nektar Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">415-482-5585</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dan Budwick&nbsp;of&nbsp;Pure Communications, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(973) 271-6085&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>dan@purecommunicationsinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Charych, D., et al., Cancer Res. 2013;73(8 Suppl):Abstract nr 482 and Data on file.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Hoch U, at al. AACR; Mol Cancer Ther. 2013;12(11 Suppl):Abstract nr B296.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 'P#J P$1  (1 0,1 ?_$ +0   $$ @,!
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MM2&UIHD;.<R/;03^]O0#;>NL%QFY7@W9I%YCK:N4?E[);0IQ+@J:EO@"%_\
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)[]'2T^_QU__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tlogo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ '0"+ P$1  (1 0,1 ?_$ ,$   ,! 0$!
M      @)"@8'!0 !  ,! 0$!              <("04&!  0   % @0$ P,#
M#@X#      $" P0%!@< $1(((1,4%2(6"3%!%S(T-5%A8C-#4V.TU"5U)K89
M0G*R(U1TE%65U5:6UCA7EQ@1  $"! 0"!@0("@H#      $" Q$2! 4 (08'
M,1-!82(4%0A1,D)B<;%2(S-S%A=RTD-3-$24M#<8@=&28Y/3)%0E5:&"L__:
M  P# 0 "$0,1 #\ .2(KRL:1JV/JFGZBE64W3L\E,1+H7SI4B+Z/>]0W%1%1
M4R:R!C$TG(8!*<@B4> XD!27V\6B[-W2WU#J*VGJ XV9E$!2%1$03 C*!' B
M(Q;*MT]9+U9G+1<J9ER@J:<MN)D2"4+3 P($0<X@C,&!'#%4>W6]T%N!M13=
MQH;E-W3U#H*EB"'UJ0-4,2D3F(I3,1-RR+&!5 P\5&RJ9_X6*D;>:UH=?Z5I
MM14<$NK3*\V#$M/)R<0>H'M)/2A23TXD7N9H.X;<:PJM,UT5--JG8<(@'F%Q
M+;@ZR.RL#@M*D]&.W*?:U/XA_P"2..V5ZI^#'!I]8?#B0RGX*NKDW/1H&DY!
MZYJ.J:KEHJ&;.IQPP:JNQ=OURD5=K+@BW)RFYO$;APRQ)"@H+YJ34XL-I<6J
MXU56XAL*=*4E4RS J)@! '%G[C<=/Z7TF=17AMM%LI*-MQU26@M03*@1"0(J
M,2,A@M?W=V\S^[8G_P!ELORC!7_EZWC_ #;7[8G\; <_F7V/_.O?L*OQ<$5M
MCVB;CK+U[4E<W*:,6U,-[5W%C3JM:U;S:Q9"0A0!CI8HK&4'Q(F\8!X,L$/;
M/:3<71E^J;YJ1"$VQ-KJT$BH#AG6WV>R"3T'/HP,]UMY]L=<Z=I;!I=;BKLJ
M[T2P%4I:$B'>WVR(=(RZ<"OZ=4I)N=V5N$7,E(.$31-:ZDEWKI9(PEI.2$HF
M345,01 0S#,. X%GEWJ:ES=:W(<<<4@M5.14HCZ!?03@N^9FDI6MG;HMMIM*
MP]2YA*0?TA'2!'#1]\N]1G8>'7MW;UXU?7@G6.9UR\MRWH&+=IB!)B13'4F>
M;<ICFQ:G^LLH'+ A56AWPWG9T+1JT]I]:5ZO?1QR(I4*&3BQPYBA]$@_AJ$H
M 4I6P.Q;^X5:G4NI$+;T53N9#-*JMQ)S:0>(:2<G7!]6DS$E*DK8[3MU5]*;
M^(M*QS]U"33]XHWF:FK (-Q/+BJ)WDHS2?N </6:SHY@ZD"@FHH!M(CD(X4W
M3.U.Z>N+;]HK6VXNB><40X]4<LNF,5+2%F*DE1/;X$QA&&')U7O%M%M_=/LQ
M=W&T5S#:06F*;FI9$();44)@E02!V(Q2"(PCC!WNL5>_;RO3K>YZ@QBM4I2*
MT.$75W>@6)%&:$>BL+-P/3B0SY/3J^5F.7L'&%K;0VMMOET[>ISRE5066Y'^
M9&26:,IRA,(1XXZ+06X.@]RFZEW28YJ*0H#G,I^5 N32PF&<93&'#^G&_M;L
M^W.7DHF*N#0B#5]3$T=\FP<OJ\0C'2AHY\XCG0*,G#CG):'34X!G\H  0X#C
M?TOM!N9K"RM:@L24KMCQ4$%54$*,BBA44DQ':2?AXXYS5N]>U.B+\]IO4*EM
MW5@(*THI"M(G0%I@I*8'LJ'#APP8-Q#W&VF;"W5J*\62CKE71N!/0[(K"=+,
M*HTJ]Z*1FGR,BW4-I_-S3I3% <R"[+[QP7=0G46T^Q"]*WTAO4ETN#K:97>8
M0PJ5;B@L'Y"9".CF# 4TTG3&\?F&1K#3R2[I:TVUEU4[7+!J$S(:04*'RU3@
M]/+. &VPWEE[/7WMO6LC*278TYE"*J--VZ=*H*TO46<1)N>4NH*:A6::X.2&
M .!T R' 'VRUC5:0UU;KU4.N]Q#P;>"E*(++WS:S F!E!G!]*<,3NOH>CUMM
M[=+%3,M>(%@N,E*4@A]GYQ"8@1$Q$A'H7BJQ^<IXQZHF<#%,Q<'(<A@,4Q3-
MSF*<ABB(" @.8"&*F/D&F6I)B"@P/]&)#TZ2FJ0E0@0XD$'X1B1VWE)5W=RY
M<5;BE)M5.H*HEY1G&&EIN19QQ5&J3^04ZEREU*B1.G9GTY)F$39!EQQ)C3UI
MOFK=2M:<M3Y%PJGG$HYCBTHBD+68D1(R2>@YXLOJ:\Z?T9I9[4]X8!MM(RVI
MP-M(4N"BA E290>TH1B1E$X-!UZ:N[A!LLLC-T<^523,<C-O7TPFNY,4!$$4
MCNXINU*H?V *BA"9^TP!QP97?+=NTALK0_1K4!DD53@)Z@5("8GK('I. 8SY
MI=FG'4H6Q7-H)@5&D:(3UD)<*H#J!/H!Q@-O.Y"\EEKCA9^MJBJ$*1EYY2W=
M74O4+ES(+4=)OWP09Y6',HX%U'N(I\<!7206*BY;Z@ -6A0N#M[N-K'1FHQI
M"]U%1X0[4&D?9>45FG6I7+G;),R2VL]I*5!*T1Z95#HMRML-$:ZTO]M;#2TW
MC3-.*RF?92E J4(1S0VX )5AQ ,JE)*D+AT3)+G_ /YKG>EY'FU++LG:>5J6
MY.CO'<N5\R^1J_GM6GE<_P"X?=,.9]W%;RI.]B')DAG"',GAZO\ [1A+-^3]
MK"+_ 'GT'-YG<U?3\R.4?HY(^MQ]F$9I/RGLXGTV\6OC+SWQ@[8R[E5BUJPE
M9M$7Z&8J1\FUIJ=D(A]H 0YR;24:)'.F/!1,!+[\3_V^TS2ZRUPQIFL44-5?
M>$A0XH6EEU;:NL)6E)(Z1$8I)N7JRKT-H"HU71(#CU&:510>"T*?:0XB/05-
MJ4 >@P/1@FMFUX:@VD[AYZTUSQ4AZ:J*<+1M:-G*A@90%3M5^GI^K$3&$"=N
M< L5-18/"HQ<D5',$RX)6SNK[AM-N$_I/4T6;;4/]WJ 3V6GDF#3X]PQ *N!
M;6%YRC JWOT5;=Y=M:?6.DX/W2FI^\TR@.T\PH3/4YZ9TP*DIXAU"D93'%%J
M@@*1Q 0$!3,("'$! 2CD(#[P'%#U>J?@Q,Q.2P#QCB16WEQE;17MAKFHQ:4V
MK15:RLRG$KNS,$7YBKR;7D*/"(N#-@R<ZM0)GXA[,25T_J)6D=;-:F0T'U45
M<XX&RJ0*[2TP*H&''C XLUJ33"=::#?THMXL(KJ!MHN!,Y1DA40F*9O5A"(X
M\<,I_>^3W_A.!_WX[_XYAD/YN:[_ *5C]J5_E85S^2ZW?]]4?LB?\[!3[<MY
MDANIIN]\<]H6/H\*,H51ZFJRJ!:;%\,S'SZ!DU"*QC#IP0[> @(";5J]V6"C
MMUO&_NE;;W3O4+=&*.A*@4NER;F(=$#%"80DZXQP(]SMCZ;:*Z6"J8N#E::Z
MX!)"F0U)RELF((6N,9^J$,(ELI=J>L?73&XU+M63JH8N$J*-B.X )VC-[/PK
MJ'3DU4  0=&C0="L1(V1%#D ##IS 47T5JRNT3?&]16Q"%W!IAY#<_JI4ZVI
ML+(]J2:8).1( .4<4&UWHVWZ^T^YIB[+6BVO5#*W),E*2RZEPM@^S/+*5#-(
M)(SACUK43M$5'?&EZAW!O9BHJ1G*L*_KZ35>G.[?KOE#F*^FW.1G"L.$@9,S
MXJ0E4Z,#E3$N0!CV:4KK)<=<4MQW 6]46E^KFJEE1*EE1]9P\2W/ NA,#RXA
M,,>+6%OO]KT!5VW;=MFFO-/1R4C83!* D>HTG@'))N451',@51B<5IQ2$8VB
MXYO"),4(9!BT2B48PB"<:E&D03*Q38$:@#8C(K8"@D"?@ F6GAEBL%*BF;I6
MVZ((31I0D-A$ @( $H3#*66$L,H0AEB.-8Y5NU;KE>7%5RG%%PKB5E9)F*RK
MM331FCG&,<\)5]7?Z9L9^CJZ_&*:PF'FW_3+']74_&SAZ_)A^@Z@^MI/B?P:
M_IS?]2+<?UVL?VOFL&GR[_PFMOX=1^\.8!'F:_C+=/P*;]V:PJ_U%;BO[P;F
MFMMZ:,>0;T$2-M_#M$!,<CJLY]VV6FA(F&8<XKUTV9&R][4<*WYA]0OZOW+1
MIRVDN-T 12MI&854.J!<R],RD-G\##<^6;3-/HK:I>J+J V[<2NL<4<BFF92
MH-1/HE2MT?68U'J'[<6-HJ8V_P Y -4RQD;0[.T]1N6Z8D*YFZ?;&E&$HY.
M>)Q, Z?B)AXCR0#&GYA-NF-)6RP5U @=V;H4T+Q A%QH3H6KK<F=SX]G&3Y:
M=SJC6=UU'07%9-4[7JN#*5&,K3RN6ML=3<K67O'#1]F-V?B_M?I*8=N>IGZ:
MAGE#U,)C 9896F&H,D7*W'4)Y&(%LY$P_*,J.&?V;U7]KMLJ2L=5-7TS*J9[
MTSLIE!/6MN1?PJ.%+WQT=]B]V*RA91+;JI]-4QZ.6^J8I'4AR=$.@)&)^-N-
MQJ=M'N$HFXU6A(#3M+5#-NY0(IH#Z0Y3F-F(]/IF@JH L;J'9,PUAD7,?=A
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M*N"JOW7ML2P)Q\J_$*2&N5R)'[@$<%7U!V9,&I%NG-&GJ 4.H.=8!*<J613
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..O\D>IZ?6];W>'O8__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
